biostudies-literatureRen YNatural Science Foundation of Hebei ProvinceThis work was supported by the Key Project of Natural Science Foundation of Hebei ProvinceNational Natural Science Foundation of China16982https://www.ebi.ac.uk/biostudies/studies/S-EPMC8379215biostudies-literatureUnknown11(1)HBV infection is recognized as a serious global health problem, and hepatitis B virus infection is a complicated chronic disease leading to liver cirrhosis (LC) and hepatocellular carcinoma (HCC). New biochemical serum markers could be used to advance the diagnosis and prognosis of HBV-associated liver diseases during the progression of chronic hepatitis B into cirrhosis and HCC. We determined whether the 4210 Da and 1866 Da polypeptides are serum metabolite biomarkers of hepatopathy with hepatitis B virus. A total of 570 subjects were divided into five groups: healthy controls, those with natural clearance, and patients with CHB, LC, and HCC. The 1866 Da and 4210 Da polypeptides were measured by Clin-ToF II MALDI-TOF-MS. There were significant differences in 4210 Da and 1866 Da levels amoScientific reports4210 Da and 1866 Da polypeptides as potential biomarkers of liver disease progression in hepatitis B virus patients.PMC837921581402729H2016206411H2016206576Gao PYang LLi TMa NRen YGao XLiu DWang JYan HLi MLiu WWang Lfalse4210 Da and 1866 Da polypeptides as potential biomarkers of liver disease progression in hepatitis B virus patients.HBV infection is recognized as a serious global health problem, and hepatitis B virus infection is a complicated chronic disease leading to liver cirrhosis (LC) and hepatocellular carcinoma (HCC). New biochemical serum markers could be used to advance the diagnosis and prognosis of HBV-associated liver diseases during the progression of chronic hepatitis B into cirrhosis and HCC. We determined whether the 4210 Da and 1866 Da polypeptides are serum metabolite biomarkers of hepatopathy with hepatitis B virus. A total of 570 subjects were divided into five groups: healthy controls, those with natural clearance, and patients with CHB, LC, and HCC. The 1866 Da and 4210 Da polypeptides were measured by Clin-ToF II MALDI-TOF-MS. There were significant differences in 4210 Da and 1866 Da levels amo2021-01-01T00:00:00Z2021 Aug2025-04-04T12:28:39.18Z2022-02-11T09:48:52.193ZS-EPMC83792153441751710.1038/s41598-021-96581-4